TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III or IV squamous cell head and neck cancer~  * T3-4, N0-3, M0~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance Status:~* ECOG 0-2~Life Expectancy:~* Not specified~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 3.0 mg/dL~* SGOT no greater than 3 times upper limit of normal~Renal:~* Creatinine no greater than 3.0 mg/dL~Other:~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No concurrent beta-adrenergic blocking agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel, amifostine, RT (Type: EXPERIMENTAL): Dose-escalation arm for paclitaxel with amifostine and RT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Polyarticular or systemic juvenile idiopathic arthritis,~* Growth velocity below the 25th percentile and or short stature ,~* Treatment with glucocorticoids for at least the previous 6 months before inclusion,~* Prepubertal stage,~* Bone age below 10 in girls and 12 in boys,~* Growth hormone levels after stimulation with clonidine or arginine above 10 ng/ml~Exclusion Criteria:~* Previous treatment with growth hormone,~* Endocrinopathy,~* Additional chronic disease beside juvenile idiopathic arthritis,~* Malignant disase,~* Chromosomal aberration or othe syndromal disease,~* Previous treatment with Oxandrolone,~* Small for gestational age,~* Elevated fasting glucose level

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pharmacology of Paracetamol Administered Per-oral Mucosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Aged over 18 years and not more than 50 years~* Males~* Values of vital signs before administration of the test products:~  * NOT between 100-140 mm Hg~ * PAD between 50-90 mm Hg~ * Radial pulse between 45-90 beats per minute~* Free from any treatment in the 7 days preceding inclusion including no use of analgesics or anti-inflammatories)~Exclusion Criteria:~* Contraindications to the administration of paracetamol~* Hypersensitivity to paracetamol~* History of hepatitis B or C~* Severe renal impairment~* Hepatic insufficiency~* Medical history and / or surgical judged by the investigator or his representative as being incompatible with the test, especially subjects with neuropathic pain~* Pathology evolutionary time of the review for inclusion~* Binge drinking, smoking (more than 10 cigarettes/day), coffee, tea or drinks containing caffeine (equivalent to more than 4 cups per day) or drug abuse~* Subject does not meet the selection criteria regarding their ability to discriminate the sensations resulting from noxious stimuli during psychometric testing~* Topic having all breaches of the oral mucosa (aphthae)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo elective primary hip arthroplasty (based on an osteoarthritis diagnosis) under spinal anesthesia~* Adult male or female (surgically sterile or post-menopausal), aged 50 years or older~* American Society of Anesthesiology (ASA) Class II or III~* Physical examination, laboratory status, vital signs, and ECG within acceptable limits for the planned surgery, as judged by the investigator~* Have been given written and verbal information by the investigator about Hemospan and the protocol, and have had the opportunity to ask questions about the study~* Patients must sign an Informed Consent form that has been reviewed and approved by the independent Ethics Committee~Exclusion Criteria:~* Hip fracture patients and nail/pin extraction procedures~* Clinical evidence of uncontrolled cardiovascular, infectious, psychiatric, metabolic or systemic disorders including diabetes and rheumatoid arthritis~* Evidence of significant hypertension with SBP \>180 mmHg, or a difference in SBP obtained in each arm that is \>15 mmHg (measured in the supine position in both arms, at screening)~* Recent history or evidence of MI or stroke (within 6 months)~* Known alcohol or drug dependency~* Currently taking oral anti-coagulant therapy; except for low-dose aspirin (acetylsalicylic acid), \<200 mg/day~* History of coagulopathy~* Involved in any investigational drug or device trial within 30 days prior to this study~* Professional or ancillary personnel involved with this study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemospan (MP4OX) (Type: EXPERIMENTAL): 4.3 g/dL MalPEG-Hb solution
- Control (Type: ACTIVE_COMPARATOR): Voluven (HES 130/0.4)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lasmiditan in Healthy Elderly Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Are overtly healthy males or females, as determined through medical history and physical examination~* Have a body mass index (BMI) of 19.0 to 35.0 kilograms per meter squared (kg/m²), inclusive, at the time of screening.~Exclusion Criteria:~* Have known allergies to lasmiditan, related compounds, or any components of the formulation.~* Are persons who have previously received lasmiditan.~* Have a history of, or electrocardiogram (ECG) findings of, clinically significant bradycardia, heart block, tachy or brady arrhythmias, or have any other abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study.~* Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data. appendectomy, splenectomy, and cholecystectomy are considered as acceptable.~* Show a history of central nervous system (CNS) conditions such as strokes, transient ischemic attacks, significant head trauma, seizures, CNS infections, migraines, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increase the risk of participating in the study.~* Show evidence of active renal disease (e.g. diabetic renal disease, polycystic kidney disease) or estimated glomerular filtration rate \<60 milliliters per minute per 1.73 meter squared (mL/min/m²).~* Have a history of syncope, presyncopy, uncontrolled vertigo, postural dizziness, or at risk for falls, as judged to be clinically significant by the investigator.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lasmiditan 200 mg (milligrams) (Type: EXPERIMENTAL): Participants received 200 mg of Lasmiditan tablet orally in the fasted state with approximately 240 (milliliter) mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
- Lasmiditan 100 mg (Type: EXPERIMENTAL): Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Continuous chest pain that lasted \> 30 minutes within the preceding 12 hours~* ST-segment elevation of at least 1 mm in 2 contiguous leads on the 12 leads ECG~* Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography~* Angiographically detected culprit coronary artery lesion deemed suitable for PCI~Exclusion Criteria:~* Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin~* Culprit lesion in saphenous vein graft~* TIMI grade II-III flow in IRA~* Additional epicardial stenosis in the IRA distal to stented segment (significant or insignificant)~* Presence of left bundle branch block~* History of prior MI~* Mechanical ventilation or inotropic support

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
- 2 (Type: ACTIVE_COMPARATOR): Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of allogeneic bone marrow, cord blood, or peripheral blood stem cell transplants are eligible~* Age \>6 years and able to complete pulmonary function testing~* Patients with evidence of sub-acute, non-infectious pulmonary dysfunction (OLD or RLD)~* Recipients of sub-ablative transplant regimens are eligible~* Recipients of donor leukocyte infusions (DLI) post-transplant are eligible~* Patients must be \> 100 days post transplant~Exclusion Criteria:~* Patients with hypotension requiring inotropic agents other than dopamine \< 5mcg/ kg/ minute for blood pressure support.~* Patients with a positive quantitative bacterial culture from the BAL fluid (≥ 104 CFU/ ml is considered positive)~* Patients whose BAL fluid is positive for significant bacterial pathogens or pathogenic nonbacterial microorganisms (as defined by protocol) by special stain, culture or PCR analysis~* Patients who are enrolled on a phase I or phase II trial for the prophylaxis or treatment of GVHD (acute or chronic) within 7 days of study entry.~* Patients with known hypersensitivity to etanercept.~* Patients who are pregnant.~* Patients with CMV seropositivity at the time of study entry. Testing may include wither CMV PCR analysis or CMV pp65 testing.~* Evidence for multi-system organ failure.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept treatment (Type: EXPERIMENTAL): Etanercept for lung injury

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 50-85 years of age~* Scheduled for a primary unilateral TKA~* Cognitive status that allows patients to consistently comprehend and repeat back directions regarding the details of the study~Exclusion Criteria:~* History of uncontrolled hypertension or uncontrolled diabetes~* Body mass index greater than 35 kg/m\^2~* Neurological, vascular or cardiac problems that significantly limit function~* Moderate or severe osteoarthritis or other orthopedic conditions in the non-operated lower extremity that limit function

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Neuromuscular Electrical Stimulation (NMES) (Type: EXPERIMENTAL): None
- Standard Rehabilitation Protocol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Standard Care Versus Celecoxib Outcome Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 60 years or over Male \& Female~* Chronic NSAIDs use for 90 days or more in a 12 month period~* Subjects who have a licensed indication for chronic non-selective NSAID or Celecoxib.~* Eligible for treatment with either Celecoxib or alternative traditional non-selective NSAID.~* Subjects who are willing to consent to their paper and electronic medical records and prescribing data to be accessed.~* Subjects who are willing to be contacted and interviewed by trial investigators.~Exclusion Criteria:~* Established cardiovascular disease including ischaemic heart disease, Myocardial Infarction, angina or acute coronary syndrome, cerebrovascular disease or cerebrovascular accident or transient ischaemic attack, established peripheral vascular disease and moderate to severe heart failure.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Celecoxib. Celebrex 200-400mg daily in divided doses
- Diclofenac (Type: ACTIVE_COMPARATOR): continue usual nsNSAID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RestoreSensor Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the indications as an appropriate surgical candidate (after successful SCS screening trial) for implant of a neurostimulation system for spinal cord stimulation (SCS) treatment of trunk and/or limb pain, per labeled indications~* 18 years of age or older~* Willing and able to attend visits and comply with the study protocol~* Capable of using the patient programmer and recharging the neurostimulator (INS), able to read and answer questionnaires in English, without assistance of a caregiver~* Males and non-pregnant females~Exclusion Criteria:~* Has had a prior implantable SCS neurostimulation system~* Currently enrolled, or plans to enroll in another investigational device or drug trial during the study~* Has unresolved legal issues related to their pain condition for which they would be receiving neurostimulation~* Requires cervical placement of leads.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 6-week AdaptiveStim followed by 6-week manual programming (Type: OTHER): None
- 6-week manual followed by 6-week AdaptiveStim programming (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosis of chronic atopic dermatitis (AD) for at least 6 months~* Moderate to severe AD (BSA at least 10%, IGA at least 3, EASI at least 16, and PP-NRS severity score at least 4)~* Recent history of inadequate response to treatment with medicated topical therapy for AD, or who have required systemic therapies for control of their disease~Exclusion Criteria:~* Acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation~* Have increased risk of developing venous thromboembolism~* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study~* Prior treatment with systemic JAK inhibitors or IL-4 or IL-13 antagonists including dupilumab, lebrikizumab or tralokinumab~* Other active non-AD inflammatory skin diseases or conditions affecting skin~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, malignancies, current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator~* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abrocitinib 200 mg plus placebo injection (Type: EXPERIMENTAL): Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
- Dupilumab 300 mg plus placebo tablets (Type: ACTIVE_COMPARATOR): Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant with T2DM on stable non-insulin antidiabetic therapy in addition to diet and exercise~* Body mass index (BMI) ≥ 25 kg/m\^2 and ≤ 40 kg/m\^2~* HbA1c 7 - 11%~* Ability and willingness to maintain a complete and accurate Subject Activity Log during the course of the trial~* Female of child-bearing potential must have agreed to use effective methods of contraception~* Ability to understand and willing to sign written informed consent~Exclusion Criteria:~* Type 1 Diabetes Mellitus (T1DM)~* T2DM with history of or current insulin therapy. Prior use during pregnancy or gestational diabetes was acceptable.~* History of ketoacidosis or ketosis-prone diabetes~* Clinically significant complications of diabetes that in the judgment of the investigator would have made participant unsuitable to participate in this trial~* History of a severe episode of hypoglycemia~* Change in non-insulin antidiabetic therapy in addition to diet and exercise \< 2 months prior to screening~* Any clinically significant cardiovascular event \< 2 months prior to screening~* Clinically significant, inadequately controlled or unstable hypertension~* Hospitalization \< 2 months prior to screening~* Major surgery \< 3 months prior to screening~* Weight loss medication (prescription or non-prescription) \< 2 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: EXPERIMENTAL): Participants were randomized to receive ranolazine for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were randomized to receive placebo to match ranolazine for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete